Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Author(s) -
Charles V. Pollack,
Paul Reilly,
Joanne van Ryn,
John W. Eikelboom,
Stephan Glund,
Richard A. Bernstein,
Robert Dubiel,
Menno V. Huisman,
Elaine M. Hylek,
CW Kam,
Pieter W. Kamphuisen,
Jörg Kreuzer,
Jerrold H. Levy,
Gordon Royle,
Frank W. Sellke,
Joachim Stangier,
Thorsten Steiner,
Peter Verhamme,
Bushi Wang,
Laura Young,
Jeffrey I. Weitz
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1707278
Subject(s) - medicine , dabigatran , idarucizumab , hemostasis , anesthesia , anticoagulant , confidence interval , thrombin time , surgery , warfarin , partial thromboplastin time , coagulation , atrial fibrillation
Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom